Navigation Links
Poniard Pharmaceuticals Announces New Efficacy and Safety Data from a Phase 2 Picoplatin Trial in Patients with Prostate Cancer
Date:2/25/2009

. Picoplatin has been evaluated in more than 750 patients and has demonstrated anti-tumor activity in multiple indications with less severe kidney toxicity (nephrotoxicity) and nerve toxicity (neurotoxicity) than is commonly observed with other platinum chemotherapy drugs. It is being studied in multiple cancer indications, treatment combinations and by two routes of administration.

In addition to the Phase 2 clinical trial in metastatic CRPC, Poniard is evaluating intravenous picoplatin in an ongoing pivotal Phase 3 trial, known as SPEAR (Study of Picoplatin Efficacy After Relapse), in small cell lung cancer. This registration trial currently is being conducted under a Special Protocol Assessment (SPA) from the U.S. Food and Drug Administration and is evaluating overall survival as the primary endpoint. Picoplatin is also being evaluated in an ongoing Phase 2 clinical trial in patients with metastatic colorectal cancer. Oral picoplatin is being evaluated in a Phase 1 clinical trial in solid tumors.

About Poniard Pharmaceuticals

Poniard Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative oncology products to impact the lives of people with cancer. For additional information please visit http://www.poniard.com.

This release contains forward-looking statements, including statements regarding the Company's results of clinical trials to date, business objectives and strategic goals, drug development plans, the potential safety and efficacy of its products in development and commercialization strategy. The Company's actual results may differ materially from those indicated in these forward-looking statements based on a number of factors, including risks and uncertainties associated with the Company's research and development activities; the results of clinical testing; the rece
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. Poniard Pharmaceuticals to Present at the BIO CEO & Investor Conference
2. Poniard Pharmaceuticals Announces Positive Tumor Response and Neuropathy Data from Phase 2 Clinical Trial of Picoplatin in Metastatic Colorectal Cancer
3. Poniard Pharmaceuticals to Present Data from Phase 2 Clinical Trials of Picoplatin in Colorectal and Prostate Cancers
4. Poniard Pharmaceuticals Announces Commercial Supply Agreement for Picoplatin
5. Poniard Pharmaceuticals to Host Third Quarter 2008 Financial Results Conference Call on October 30
6. Poniard Announces Positive Incremental Efficacy and Safety Data from Phase 2 Picoplatin Trial in Patients With Metastatic Colorectal Cancer
7. Poniard Announces Positive Incremental Efficacy and Safety Data From Ongoing Phase 2 Picoplatin Trial in Hormone-Refractory Prostate Cancer
8. Poniard Pharmaceuticals to Present at the JMP Securities Healthcare Focus Conference
9. Poniard Pharmaceuticals Announces Upcoming Conference Participation
10. Poniard Pharmaceuticals to Present at the 4th Annual Moores UCSD Cancer Center Translational Oncology Symposium
11. Poniard Pharmaceuticals Announces Upcoming Conference Participation

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)...f.,Nov.24/PRNewswire-FirstCall/--NeurogesX,Inc.(Na...elopingandcommercializingnovelpainmanagementtherap...hiefExecutiveOfficer,isscheduledtopresentatthe21st...ember1-2,2009atTheNewYorkPalaceHotelinNewYork,NewY...ncialOfficer,willbeavailabletorespondtoquestionsdu...
(Date:11/24/2009)...4/PRNewswire/--BlueMarbleEnergyCorp.announcedtoday...ty(OPDA)wererecentlyawarded$2millionbyWashingtonSt...private/publicpartnershiptoconstructthestate,sfirs.... ,, "Thisinvestmentwillsignificantlyspeedthede...LincolnCounty,"saidBlueMarbleEnergyCEOKellyOgilvie...
(Date:11/24/2009)...cyendpointhasbeenmetforpatientswithadvanced-stage,...v.24/PRNewswire-FirstCall/-AEternaZentarisInc.(NAS...ceuticalcompanyfocusedonendocrinetherapyandoncolog...dywithitstargetedcytotoxicpeptideconjugate,AEZS-10...tendometrialcancer.Inapersonalizedhealthcareapproa...
(Date:11/24/2009)...er24/PRNewswire-FirstCall/--Shireplc(LSE:SHP,NASD...pany,today,announcedthatithassubmittedaMAAtotheEur...ny,senzymereplacementtherapyindevelopment,forthetr...ng,applicationforvelaglucerasealfathathasbeensubmi...anada. , Basedonaglobalsupplyshortageofthecur...
Breaking Biology Technology:NeurogesX to Present at Piper Jaffray Health Care Conference 2NeurogesX to Present at Piper Jaffray Health Care Conference 3Blue Marble Energy, OPDA Awarded $2M by WA's Community Economic Revitalization Board 2AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 2AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 3AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 4Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 2Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 3
... BioTime, Inc., (OTCBB:BT...bryome Sciences, Inc., have signed a manufacturing...m Cell Corporation (OTCBB:ISCO) through its wholly...ne) to jointly produce and distribute hundreds of ... along with corresponding data and reagents. The m...
...EYKJAVIK, Iceland, June 25 /PRNewswire-FirstCall/ ...d that it will webcast live the presentations,at t...rk., The presentations will be delivered on Monda...6pm British Summer time, at the Gansevoort hotel,i...imately three and a half,hours. The webcast can be...
...OSTON, June 24 PAREXEL International,Corporation ...uss,forward-looking earnings expectations for the ..., 2008), for Fiscal Year 2008 in its entirety, and...ld tomorrow in Boston,Massachusetts. It should be ...act from the potential acquisition of ClinPhone pl...
Other Biology Technology: BioTime, Inc. and Embryome Sciences, Inc. Sign Agreement With International Stem Cell Corporation to Provide Unique Human Stem Cell Lines for Research Use 2 BioTime, Inc. and Embryome Sciences, Inc. Sign Agreement With International Stem Cell Corporation to Provide Unique Human Stem Cell Lines for Research Use 3 BioTime, Inc. and Embryome Sciences, Inc. Sign Agreement With International Stem Cell Corporation to Provide Unique Human Stem Cell Lines for Research Use 4 BioTime, Inc. and Embryome Sciences, Inc. Sign Agreement With International Stem Cell Corporation to Provide Unique Human Stem Cell Lines for Research Use 5deCODE genetics to Webcast Presentations at Annual R&D Event 2deCODE genetics to Webcast Presentations at Annual R&D Event 3PAREXEL International Updates Earnings Guidance in Conjunction with Its Investor Day 2PAREXEL International Updates Earnings Guidance in Conjunction with Its Investor Day 3PAREXEL International Updates Earnings Guidance in Conjunction with Its Investor Day 4
(Date:11/24/2009)...OUGE Antarctica has long held secrets of the eart...cently, there has been very little information on ...es of ice for millions of years. Now, a team of re...ave been funded to the tune of $10 million dollars...t to the bottom of things literally. These scient...
(Date:11/24/2009)...ease is available in Spanish . , The presen...els of inflammatory substances in the blood, hinde...wn by a research project of the University of Nava...tist at the School of Pharmacy. , The project, e...relation to the control of body weight and inflamm...
(Date:11/23/2009)...idge, Mass. November 23, 2009 Applied mathematic... ( Hosta lancifolia ), a characteristic long leaf ...ed ripples along the edges. The simple cause of th...g from bending during differential growthwas revea...ng foam ribbons. , Haiyi Liang, a postdoctoral s...
Breaking Biology News(10 mins):LSU gets to the bottom of things -- in Antarctica 2It can be predicted the reaction obese patients will have to a diet 2The cause behind the characteristic shape of a long leaf revealed 2Nonprofit nursing homes provide better care major study finds 54903 1Nonprofit nursing homes provide better care major study finds 54903 2Tobacco Free Kids Welcomes Formation of FDAs Center for Tobacco Products and Selection of Center Director 54902 1Tobacco Free Kids Welcomes Formation of FDAs Center for Tobacco Products and Selection of Center Director 54902 2Nutrisystem Now Offers Double the Fresh Frozen Food for the Same Low Monthly Cost 54898 1Nutrisystem Now Offers Double the Fresh Frozen Food for the Same Low Monthly Cost 54898 2Nutrisystem Now Offers Double the Fresh Frozen Food for the Same Low Monthly Cost 54898 3
... their four-legged friend seem equally delighted t...may wonder if animals can tell when time passes. N...tern Ontario in London, Canada may bring us closer...f the research, entitled Episodic-Like Memory in R...n the current issue of the journal Science, which ...
...dicates that wild salmon may account for just 10 p...ulation, while the vast majority of the fish come ...ling in light of the disastrous decline in the pop...losure of the 2008 season for commercial and recre... in the management of salmon populations has been ...
...5 years of biodiversity and climate change researc...ay announced formation of its Asia Center to forge...ion and sustainable use of environmental resources...nd involving St. Josephs University in Philadelphi...ective universities in China and among the worlds ...
Other Biology News:Are animals stuck in time? 2Hatchery fish outnumber wild chinook salmon in troubled fall run 2Hatchery fish outnumber wild chinook salmon in troubled fall run 3Hatchery fish outnumber wild chinook salmon in troubled fall run 4Hatchery fish outnumber wild chinook salmon in troubled fall run 5Academy establishes Asia Center to protect the environment 2Academy establishes Asia Center to protect the environment 3Academy establishes Asia Center to protect the environment 4
Gtporator (4 ml) from GEN-TREND s.r.o.
UltraClean Plant DNA Isolation Kit from Mo Bio Laboratories, Inc.
Acridine orange, hemizinc salt from Research Organics, Inc.
Agarose, medium EEO, Molecular Biology Grade from Research Organics, Inc.
Biology Products: